ArticleCellular & molecular immunology2010
Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells.
Article in Cellular & molecular immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Comprehensive analysis of immunoglobulin expression in the mouse brain from embryonic to adult stages.Journal of neuroinflammation · 2025Article
- Comparison of Non B-Ig and B-Ig.Advances in experimental medicine and biology · 2024Review
- The Gene Rearrangement and Transcriptional Regulation of Non B Cell-Derived Immunoglobulin.Advances in experimental medicine and biology · 2024Review
- Non B Cell-Derived Immunoglobulin, A Brighter Horizon for the Future.Advances in experimental medicine and biology · 2024Review
- Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer.BMC cancer · 2023Article
- Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.Cancer science · 2023Article
- SIA-IgG confers poor prognosis and represents a novel therapeutic target in breast cancer.Bioengineered · 2022Article
- Cancer-Cell-Derived IgG and Its Potential Role in Tumor Development.International journal of molecular sciences · 2021Review
- Current insights into the expression and functions of tumor-derived immunoglobulins.Cell death discovery · 2021Review
- Immunoglobulin Expression in Cancer Cells and Its Critical Roles in Tumorigenesis.Frontiers in immunology · 2021Review
- Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies.Frontiers in oncology · 2021Review
- Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.Cellular & molecular immunology · 2020Article
- Prognostic Molecular Signatures for Metastatic Potential in Clinically Low-Risk Stage I and II Clear Cell Renal Cell Carcinomas.Frontiers in oncology · 2020Article
- Cancer cell-derived immunoglobulin G activates platelets by binding to platelet FcγRIIa.Cell death & disease · 2019Article
- Expression of immunoglobulin G in human podocytes, and its role in cell viability and adhesion.International journal of molecular medicine · 2018Article
- AID expression increased by TNF-α is associated with class switch recombination of Igα gene in cancers.Cellular & molecular immunology · 2016Article
- Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis.Oncotarget · 2015Article
- IGK with conserved IGΚV/IGΚJ repertoire is expressed in acute myeloid leukemia and promotes leukemic cell migration.Oncotarget · 2015Article
- Oct-2 forms a complex with Oct-1 on the iNOS promoter and represses transcription by interfering with recruitment of RNA PolII by Oct-1.Nucleic acids research · 2015Article
- Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells.Oncotarget · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The restriction of immunoglobulin (Ig) expression to B lymphocytes is well established. However, several reports have confirmed that the Ig gene can be expressed in many non-B cancer cells and/or some normal cells. Our aim is to determine whether the Ig gene promoter can be activated in non-B cancer cells and to identify the regulatory mechanism for Ig gene expression. Our results show that the Ig promoter of VH4-59 was activated in several non-B cancer cell lines. Moreover, two novel positive regulatory elements, an enhancer-like element at -800 to -610 bp and a copromoter-like element at -610 to -300 bp, were identified in two epithelial cancer cell lines, HeLa S3 and HT-29. The octamer element (5'-ATGCAAAT-3') located in the Ig promoter, a crucial element for B-cell-derived Ig gene transcription, was also very important for non-B-cell-derived Ig gene transcription. More importantly, we confirmed that octamer-related protein-1 (Oct-1), but not Oct-2, was a crucial transcriptional factor for Ig gene transcription due to its ability to bind to the octamer element of the Ig promoter in epithelial cancer cells. These results suggested the presence of a distinct regulatory mechanism for Ig gene expression in non-B cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.